Market Intelligence, Clinical Progress, and High-Purity Reagents for Non-Opioid Pain and Sensory Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TRPV1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length) | TRPV1 Full-Length ORF Lentivirus – HEK293 Expressed, Sequence Verified, Endotoxin <1EU/ug. Preserves native tetrameric conformation for functional screening. | View TRPV1 Products |
| Antigen (ECD/Mutant) | TRPV1 ECD-Fc / Mutant Protein – High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. For binding and selectivity assays. | View TRPV1 Products |
| Gene Delivery | TRPV1 Promise-ORF / Lentivirus – Full-length ORF for stable cell lines. High Titer, Puromycin Selection. | View TRPV1 Products |
| Benchmark Ab | Anti-TRPV1 Reference Antibody – Recombinant positive control for binding assay validation. Sequence Verified. | View TRPV1 Products |
| Validator | TRPV1 siRNA Set – For knockdown verification and specificity controls. | View TRPV1 Products |
| Related Target A | TRPA1 – Synergistic nociceptor channel; co-expressed in sensory neurons for counter-screening. | View TRPA1 Products |
| Related Target B | TRPM8 – Opposing thermosensor; critical for cold allodynia and selectivity panels. | View TRPM8 Products |
| Related Target C | TRPV2 – Subfamily off-target counter-screening (TRPV2 shares ~50% homology with TRPV1). | View TRPV2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation & Ion Channel Activity | HEK293 Expressed Lentivirus. Full-length TRPV1 with native glycosylation and tetramer assembly. Sequence Verified. |
| Cross-species Cyno / Mouse / Rat Eval | Human / Cyno / Mouse / Rat Ortholog ORF Lentivirus Panel. Sequence Verified, Ready for stable line generation. |
| TRP Subfamily Off-target (TRPV2/3/4, TRPA1) | High-purity ortholog panel proteins & cell lines available for selectivity screening (Sequence Verified by Mass Spec). |
| False Positives / Non-specific Binding | Validated siRNA included for knockdown specificity checks. Endotoxin Controlled (<1EU/ug). |
| Species Cross-Reactivity (Protein Level) | Human/Mouse/Cyno ortholog proteins available with >95% purity for ELISA/SPR. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
Live TRPV1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPV1 therapeutics is intensifying, with major players shifting focus from systemic antagonists to peripherally restricted and topical modalities. First-generation small-molecule antagonists (e.g., AMG-517, SB-705498) suffered on-target hyperthermia liabilities, prompting a strategic pivot. The next wave of R&D includes biased agonists, allosteric modulators, and peripherally restricted formulations to circumvent central thermoregulatory effects. Key players include Grünenthal (topical agonists), Amgen/Biogen (systemic antagonists with improved selectivity), and Centrexion (injectable capsaicin formulation for osteoarthritis).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | GSK, Amgen, Biogen, Abbott, Bayer, Grünenthal, Centrexion | Osteoarthritis Pain, Dental Pain, Chronic Pain, Cough | Calcium Flux / Ion Flux Assay (Need lentivirus-stable TRPV1+ HEK293 cell line) |
| Peptide / Natural Product | RTX (Sorrento/Scilex), Capsaicinoids | Bladder Pain Syndrome, Neuropathic Pain | Binding & Internalization Assay (Need cell surface expression system) |
| Topical / Transdermal | Multiple Biotech / Pharma Partners | Dry Eye, Post-herpetic Neuralgia, Neuropathic Pain | Keratinocyte & Sensory Neuron Co-culture (Need Endotoxin Controlled, Sequence Verified reagents) |
| Biologic / Antibody | Emerging Biotech | Refractory Pain | Epitope Mapping (Need full-length Lentivirus expression system) |
| Allosteric Modulator | Academic / Preclinical | Inflammation | Binding Site Validation (Need mutant protein panel) |
Key Mutations & Polymorphisms
TRPV1 exhibits naturally occurring variants that may affect drug binding and efficacy. Notable missense variants documented in UniProt Q8NER1 include rs222749, rs222747, and rs224534. These mutations alter channel gating or ligand sensitivity, making mutant protein reagents essential for assessing drug specificity across genetic backgrounds. TarMart offers sequence-verified mutant TRPV1 proteins (ECD-Fc) for such studies.
Related Targets for Cross-Selling
- TRPA1 (Mustard Receptor): Co-expressed with TRPV1 in sensory neurons; key for cold pain and chemical nociception. Dual TRPV1/TRPA1 inhibitors are a hot direction. (View TRPA1 Products)
- TRPM8 (Cold Receptor): Opposing thermosensor; critical for cold allodynia and selectivity panels. (View TRPM8 Products)
- TRPV2: ~50% homology with TRPV1; major off-target risk. Always include TRPV2 in counter-screening. (View TRPV2 Products)
- NGF: Nerve growth factor upregulates TRPV1; anti-NGF antibodies (e.g., Tanezumab) combined with TRPV1 modulators are under investigation. (View NGF Products)
- CGRP: Downstream effector in the TRPV1-CGRP pain axis. (View CGRP Products)